Real-World Clinical Experience of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Olaparib + Abiraterone (PROceed)

Trial Identifier: D0817R00074
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme LLC
NCTID:: NCT06380738
Start Date: February 2024
Primary Completion Date: January 2027
Study Completion Date: January 2027
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GERMANY Aschaffenburg, GERMANY
GERMANY Berlin, GERMANY
GERMANY Duisburg, GERMANY
GERMANY Franckfurt, GERMANY
GERMANY Halle, GERMANY
GERMANY Herzogenaurach, GERMANY
GERMANY Leipzig, GERMANY
GERMANY Lueneburg, GERMANY
GERMANY Muhlheim, GERMANY
GERMANY Nurnberg, GERMANY
GERMANY Russelsheim, GERMANY
GERMANY Speyer, GERMANY
GERMANY Wetzlar, GERMANY